Trial Profile
NN1250-3582: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing Efficacy and Safety of SIBA and Insulin Glargine Both Administered Once Daily in a Basal-bolus Regimen With Insulin Aspart as Mealtime Insulin ± Treatment With Metformin, ± Pioglitazone in Subjects With Type 2 Diabetes Currently Treated With Insulin Qualifying for Intensified Treatment/NN1250-3667: An Extension Trial to NN1250-3582 Comparing Safety and Efficacy of NN1250 and Insulin Glargine, Both With Insulin Aspart as Meal-time Insulin ± OADs in Type 2 Diabetes (BEGIN: BB)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary) ; Insulin aspart; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms BEGIN; BEGIN-BBT2D
- Sponsors Novo Nordisk
- 01 Dec 2015 Results of pooled analysis of 5 phase III trials (NCT01392573, NCT01617434,NCT00972283, NCT01006291 and NCT01045447) published in the Diabetes Therapy
- 23 Oct 2012 Planned number of patients changed from 819 to 1403 as reported by EudraCT2008-005777-35.
- 01 May 2012 Results published in the Lancet.